VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Cov19VaxKB
Host Responses
VaximmutorDB
VIGET
Vaxafe
Vaxar
Vaxism
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign2
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UM Logo

Vaccine Detail

rORFV-D1701-V-HAh5n (H5N1)
Vaccine Information
  • Vaccine Name: rORFV-D1701-V-HAh5n (H5N1)
  • Target Pathogen: Influenza virus
  • Target Disease: Influenza (flu)
  • Vaccine Ontology ID: VO_0004765
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Baboon
  • Vector:
  • Preparation: ORFV recombinants expressing the hemagglutinin (HA) or nucleoprotein (NP) of the highly pathogenic avian influenza virus (HPAIV) H5N1 (Rohde et al., 2013).
  • Immunization Route: Intramuscular injection (i.m.)
Host Response

Mouse Response

  • Vaccination Protocol: The mice were immunized with varying doses of D1701-V-HAh5n (Rohde et al., 2013).
  • Vaccine Immune Response Type: VO_0000286
  • Challenge Protocol: Mice were instilled intranasally (i.n.) under anaesthesia [20] using 50 µl of the indicated mouse 50% lethal dose (MLD50) of HPAIV. For BALB/c mice 1× MLD50 corresponded to 7×10^1 plaque-forming units (pfu) of strain MB1, 2×10^1 pfu of strain SN1 and 1×10^4 pfu of strain PR8. For C57BL/6 mice 2×10^3 pfu of strain MB1, 1.4×103^ pfu of strain PR8 matched to 1× MLD50 (Rohde et al., 2013).
  • Efficacy: Despite adequate expression of NP, the recombinant D1701-V-NPh5 completely failed to protect mice from lethal challenge. However, the H5 HA-expressing recombinant D1701-V-HAh5n mediated solid protection in a dose-dependent manner. Two intramuscular (i.m.) injections of the HA-expressing recombinant protected all animals from lethal HPAIV infection without loss of body weight. Notably, the immunized mice resisted cross-clade H5N1 and heterologous H1N1 (strain PR8) influenza virus challenge (Rohde et al., 2013).
References
Rohde et al., 2013: Rohde J, Amann R, Rziha HJ. New Orf virus (Parapoxvirus) recombinant expressing H5 hemagglutinin protects mice against H5N1 and H1N1 influenza A virus. PloS one. 2013; 8(12); e83802. [PubMed: 24376753].